Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: A method of reducing the percentage of Epstein-Barr virus genome-carrying cells which exhibit Epstein-Barr virus early antigen induction, where the Epstein-Barr virus genone-carrying cells have been cultivated in the presence of at least one tumor-promoting chemical. The method is carried out by cultivating Epstein-Barr virus genome-carrying cells in the presence of a tumor-promoting chemical; and treating the Epstein-Barr virus genome-carrying cells with betanins. The betanins are effectively reduce the incidence of Epstein-Barr virus early antigen induction in the cultivated Epstein-Barr virus genome-carrying cells.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

Abstract: A product which contains a health-promoting component and a process for preparing such a product, in the present invention, using a pulse crop as a raw material. The product accomplishes health promotion very effectively by means of at least one member of the group consisting of liver function improving constituents, cardiac function improving constituents, anti-inflammatory constituents, antifat constituents, antioxidation consititents, antimutagen constituents, and components which have an intestine-regulating effect in single-stomached animals; and the method produces such a product with good efficiency. The product of the present invention can be used directly “as is”; and alternatively, specified components may be concentrated or may be usefully utilized in applied products which use the product of the present invention as a raw material, e. g., food products, livestock feeds, pet foods or drug raw materials, etc.

Abstract: The present invention relates in general to a method of producing a dry, free-flowing mixture of liquid tocopherols. The present invention also relates to a dry free-flowing vitamin powder.

Abstract: Chewable tablets and particulate food and pharmaceutical products are disclosed which are made from agglomerates comprising an alcohol sugar such as mannitol and a high intensity sweetener such as Aspartame from which agglomerate tablets may be directly compressed, and processes for making the agglomerates and tablets. The tablets or particulate product containing the agglomerate may contain active ingredients blended with the agglomerate or as part of the agglomerate structure. Tablets and particulate products according to the invention can contain active ingredients such as pharmaceuticals (e.g., antacids, analgesics, cough medicine, drugs, etc.) breath sweeteners, vitamins and dietary supplements, to name a few. The high intensity sweetener containing agglomerates can also be used to make solid food mix type products such as sugar free ice tea mixes.

Abstract: Paraffinic oils which comprise in the range of from 45% to 100% basis mass per mass of one or more paraffinic hydrocarbon(s) and have an average molecular weight in the range of from 100-200 are useful as antifoam agents, especially in a surfactant-containing concentrate or an adjuvant concentrate for crop protection use.

Abstract: Silica compositions for abrasive systems in dentifrice formulations are disclosed. The silica abrasive system comprises (a) silica gels having a median particle size below 7 microns, a pH of from about 6 to about 11 and powder RDA's of from 100 to about 200 and (b) silica gels or precipitates having a median particle size of 7 microns or greater and powder RDA's of from 50 to about 180. Silica (a) is preferably prepared by contacting a hydrous silica gel with an alkaline medium. Dentifrice compositions comprising the abrasive system has an RDA of 150 or less and PCR's of at least 80 and up to about 150, and an REA of less than about 30 (as measured on the IU scale).

Abstract: The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.

Abstract: A method of reducing the percentage of Epstein-Barr virus genome-carrying cells which exhibit Epstein-Barr virus early antigen induction, where the Epstein-Barr virus genome-carrying cells have been cultivated in the presence of at least one tumor-promoting or tumor-inducing chemical. The method is carried out by cultivating Epstein-Barr virus genome-carrying cells in the presence of a tumor-promoting or tumor-inducing chemical; and treating the Epstein-Barr virus genome-carrying cells with a synthetic fluorescein dye. The dyes effectively reduce the incidence of Epstein-Barr virus early antigen induction in the cultivated Epstein-Barr virus genome-carrying cells.

Abstract: A method of treating a group of mammals which have been topically exposed to a tumor promoter or a tumor initiator so as to reduce the percentage of mammals which exhibit formation of epidermal tumors. The topically exposed tissue is treated with an acetone solution containing a defined amount of a synthetic colorant. Preferably, the synthetic colorant is tartrazine or erythrosine B.

Abstract: The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthetic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents.

Abstract: A method of preventing inflammation of epidermal tissue resulting from exposure to a chemical by topically applying an acetone solution containing a natural colorant to the exposed tissue. The natural colorant is preferably a paprika extract containing a mixture of capsanthin, capsorubin, and their acyl esters, or an annatto seed extract containing a mixture of cis-bixin, trans-bixin, and cis-norbixin.

Abstract: A process for treating a wood substrate with a water-based formulation containing a wax in order to confer water repellency to the substrate comprising the steps of: (a) placing the substrate in a treatment vessel and reducing the pressure in the vessel to remove air in the pores of the substrate; (b) contacting the substrate in the vessel, while reduced pressure is present in the vessel, with the formulation to allow the formulation to flow into said pores, said contacting being carried out at a temperature at or above that required to cause the wax to change into a molten state; (c) applying a positive pressure to the vessel to force the formulation into said pores; and (d) releasing the pressure in the vessel and removing the resultant wood substrate from the vessel.

Abstract: A method of preparing a biocidal material comprises taking a biocidal material comprising a biocide having a log P value of at least 1.5 immobilized by hydrophobic exclusion on a support having a hydrophobic surface which has been used for inhibiting microbial growth in an aqueous medium, extracting the biocide from the biocidal material with a solvent, and immobilizing the extracted biocide by hydrophobic exclusion on a support having a hydrophobic surface.

Abstract: The present invention relates to new active compound combinations of pyrethroids with insect development inhibitors, for achieving a long-term effect against animal pests with high effectiveness, fewer environmentally polluting properties and a toxicologically favourable control concept.

Abstract: A method of reducing the percentage of Epstein-Barr virus genome-carrying cells which exhibit Epstein-Barr virus early antigen induction, wherein the Epstein-Barr virus genome-carrying cells have been cultivated in the presence of a tumor-promoting chemical and/or a tumor-inducing chemical. The method is performed by: a) cultivating Epstein-Barr virus genome-carrying cells in the presence of a tumor-promoting chemical and/or a tumor-inducing chemical; and b) treating the Epstein-Barr virus genome-carrying cells with a synthetic anthraquinone colorant containing a sulfonated phenylamino group. The colorant is effective to reduce the incidence of Epstein-Barr virus early antigen induction in the cultivated Epstein-Barr virus genome-carrying cells.

Abstract: A fragrance composition which contains 1,3-dimethoxy-5-methylbenzene in an amount of from 0.01 to 30% by weight as a fragrance modifier that provides a sedative effect. 1,3-Dimethoxy-5-methylbenzene used in the present invention can exhibit a sedative effect not only by itself but also when mixed with various formulations of jasmine, floral and the like types having stimulative effects. Also, since a single chemical is used as an active ingredient, the present invention is more effective than the sedative function of natural essential oil from a viewpoint of sedation. In addition, since 1,3-dimethoxy-5-methylbenzene itself has a mild scent, its sedative effect can be obtained without altering original fragrance of interest.

Abstract: Use of polymers which contain (a) 0.1 to 100 mol % of vinylamine units or ethyleneimine units, (b) 0 to 99.9 mol % of units of at least one monomer from the group consisting of open-chain N-vinylcarboxamides, vinyl formate, vinyl acetate, vinyl propionate, vinyl alcohol, C1- to C6-alkyl vinyl ethers, monoethylenically unsaturated C3- to C8-carboxylic acids, their esters, nitriles, amides and anhydrides, N-vinylurea, N-vinylimidazoles and N-vinylimidazolines and (c) 0 to 5 mol % of units of monomers having at least two ethylenically unsaturated double bonds, in copolymerized form, the sum of (a), (b) and (c) in mol % always being 100, as biocide.

Abstract: Topical gelled compositions comprising a drug which causes vasodilation, and optionally prostaglandin E1, dispersed within a polymer matrix, and methods of treating sexual dysfunction, including both male and female sexual dysfunction, using said compositions.